Markets

Insider Trading

Hedge Funds

Retirement

Opinion

UnitedHealth Group (UNH) vs. Eli Lilly and Company (LLY): Which Healthcare Stock Offers the Better Dividend?

UnitedHealth Group Incorporated (NYSE:UNH) and Eli Lilly and Company (NYSE:LLY) both have respectable dividend records, but the two companies are at different stages of their dividend journeys. UNH has the longer history. It has paid dividends since 1990 and has raised its payout for 16 straight years. Its quarterly dividend now stands at $2.32 per share.

Lilly has increased its dividend for 11 consecutive years. While that streak is shorter, the growth has been considerably faster. The company raised its dividend by 15% for seven straight years through 2025, bringing its quarterly payout to $1.73 per share.

UnitedHealth Group Incorporated (NYSE:UNH) clearly has the longer dividend record. Eli Lilly and Company (NYSE:LLY)’s advantage is the pace at which its payout has grown.

Photo by Jp Valery on Unsplash

Yield and Valuation

The gap is even more noticeable when it comes to yield. UNH offers roughly a 2% dividend yield, while Lilly’s is below 1%. For investors looking for income from their holdings today, UnitedHealth Group Incorporated (NYSE:UNH) has the clear advantage.

The valuation gap is just as wide. UNH trades at roughly 25 times trailing earnings and about 22 times forward earnings, compared with close to 40 times trailing earnings for Eli Lilly and Company (NYSE:LLY). Lilly’s higher valuation is not difficult to understand. Its business is growing much faster, helped in large part by its diabetes and obesity drugs. Still, investors are paying considerably more for each dollar of Lilly’s earnings. UNH, by comparison, looks much more reasonably valued, which is important for investors weighing the stock primarily for its dividend.

Dividend Prospects

Eli Lilly and Company (NYSE:LLY) has the stronger setup for dividend growth over the longer term. Its payout remains small relative to earnings, leaving plenty of room for increases. Much of that potential comes from the underlying business, which continues to grow at a rapid pace. Revenue jumped 45% to $65.2 billion in 2025, while earnings also posted strong growth. If Mounjaro, Zepbound, and the rest of Lilly’s drug pipeline continue to perform well, the company should have the earnings power to keep increasing its dividend at a healthy rate.

The drawback is the starting yield. At less than 1%, Lilly offers little income today. Investors choosing the stock for its dividend are largely counting on that payout becoming much more meaningful over the years ahead.

UnitedHealth Group Incorporated (NYSE:UNH) presents a different picture. It is unlikely to match Eli Lilly and Company (NYSE:LLY)’s dividend-growth rate, but investors start with a much higher yield. UNH raised its dividend to $2.32 per share in 2026, while second-quarter results included $11.1 billion in operating cash flow. The company also raised its 2026 adjusted EPS outlook to $19.50-$20.00 per share.

Those figures provide a reasonable earnings and cash-flow cushion for the dividend. The bigger issue is the pace of future growth. UNH still faces higher medical costs and pressure in its Medicare Advantage business, which could make it harder to increase the payout quickly.

Final Conclusion

At current prices, UnitedHealth Group Incorporated (NYSE:UNH) looks like the better choice for dividend investors. The stock offers more income, a longer record of dividend increases, and a considerably lower valuation. Taken together, those factors make the dividend proposition more balanced. Eli Lilly and Company (NYSE:LLY) is more compelling for investors focused on future dividend growth rather than income today. Continued earnings growth could support double-digit dividend increases for years. The trade-off is the premium valuation and a starting yield of less than 1%.

The choice comes down to what investors want from the dividend. UNH is the better income-and-value play, while LLY is the better dividend-growth play. For a dividend portfolio today, UNH offers the more balanced combination of yield, history, and valuation. Lilly is better suited to investors willing to accept less income now in exchange for the potential of faster dividend growth in the years ahead.

While we acknowledge the risk and potential of UNH and LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than UNH and LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: PPG Industries (PPG) is an Underrated Dividend Stock Worth a Closer Look and Stanley Black & Decker (NYSE:SWK)’s 58-Year Dividend Streak is Hard to Ignore

Disclosure: None. This article is originally published at Insider Monkey.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.